Advisory Committees
-
Briefing Information for the October 18, 2010 Meeting of the Cardiovascular and Renal Drugs Advisory Committee
Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance
FDA
Disclaimer
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
Amgen, Inc
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
-
-







